ANI Pharmaceuticals Q1 Revenue Rises 24% to $124.7M, EBITDA Climbs 30%
ANI Pharmaceuticals reported Q1 2026 revenue of $124.7 million, a 24% year-over-year increase driven by higher volumes in its generic contract manufacturing segment. Adjusted EBITDA rose 30% to $23.6 million and management reaffirmed full-year revenue guidance of $520 million to $540 million with a 21%–22% EBITDA margin target.
1. Q1 Financial Results
ANI Pharmaceuticals posted Q1 2026 revenue of $124.7 million, up 24% from Q1 2025, reflecting robust demand in its contract manufacturing operations. GAAP net income reached $9.2 million, or $0.58 per share, compared with $6.7 million, or $0.42 per share, a year earlier.
2. Margin Expansion Drivers
Adjusted EBITDA climbed 30% to $23.6 million, fueled by improved plant efficiencies and cost savings across its U.S. and European facilities. Management attributed the margin uplift to higher throughput from recently commissioned production lines and disciplined overhead controls.
3. Outlook and Guidance
Executives reaffirmed full-year 2026 revenue guidance of $520 million to $540 million and an EBITDA margin target of 21%–22%. The company plans to invest approximately $20 million in capacity expansion and advance its late-stage development pipeline through year-end.